Belsomra (Suvorexant) for Adults 65 and Older: School, Work, and Daily Activity Considerations

What Is Suvorexant and Why Does the Geriatric Dose Differ?

Suvorexant (brand name Belsomra) is a dual orexin receptor antagonist approved by the FDA in 2014 for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance. It works by blocking orexin A and orexin B signaling at OX1 and OX2 receptors, suppressing the brain's arousal drive rather than broadly sedating the central nervous system the way benzodiazepines do. The FDA-approved prescribing information specifies a recommended starting dose of 10 mg for all adults, including those 65 and older, with a ceiling of 20 mg nightly. [1]

Why Age Changes the Pharmacokinetics

Aging alters drug metabolism in ways that extend suvorexant exposure. The mean plasma half-life of suvorexant is approximately 12 hours in the general adult population, but hepatic clearance declines with age and body composition shifts affect volume of distribution. [2] A dedicated pharmacokinetic analysis published in the Journal of Clinical Pharmacology found modestly higher suvorexant exposure in older versus younger subjects, supporting the conservative 10 mg starting recommendation for patients 65 and older. [3]

The Orexin System in Aging

The orexin (hypocretin) system regulates sleep-wake transitions and contributes to muscle tone maintenance. Older adults already experience natural attrition of orexin-producing neurons in the lateral hypothalamus. [4] Pharmacologically blocking residual orexin signaling with suvorexant therefore produces a proportionally larger effect on daytime alertness and motor coordination in geriatric patients than in younger cohorts.

Next-Day Sedation: The Core Activity Risk for Older Patients

Next-day residual sedation is the most clinically significant activity-related concern for adults 65 and older taking suvorexant. The Phase 3 key trials (pooled N=3,022 across Studies 1 and 2) reported somnolence as the most common adverse event, occurring in approximately 7% of patients receiving 20 mg versus 3% on placebo. [1] In older subgroup analyses, rates of somnolence and next-day impairment were numerically higher than in younger adults.

Driving and Motorized Equipment

The FDA prescribing label for suvorexant carries an explicit warning: patients should be counseled that morning driving ability may be impaired even if they feel awake. [1] A randomized crossover study by Vermeeren et al. Assessed on-road driving performance the morning after suvorexant 20 mg administration. Mean standard deviation of lateral position (SDLP), a validated measure of driving impairment, was significantly elevated versus placebo (P<0.001), an effect comparable in magnitude to a blood alcohol concentration of 0.05% in older drivers. [5] Older adults should plan no driving or operation of power tools, ladders, or heavy machinery within the first 7 hours after waking if any residual drowsiness exists.

Balance, Gait, and Fall Risk

Falls are the leading cause of fatal and non-fatal injury in adults 65 and older in the United States, accounting for approximately 36 million falls and 32,000 deaths annually according to CDC surveillance data. [6] Suvorexant's effect on muscle relaxation and postural control is more modest than that of benzodiazepines, but it is not absent. The FDA labeling specifically notes that patients taking suvorexant were more likely to report falls and that prescribers should counsel patients about fall risk, particularly for those who get out of bed during the night. [1]

A pooled safety analysis from the suvorexant Phase 3 program found a fall-related adverse event rate of 1.1% with suvorexant 20 mg versus 0.6% with placebo across all age groups. [7] In the geriatric subpopulation, absolute risk may be higher given baseline gait and balance deficits common in this age group. Patients should be advised to use nightlights, keep a clear path to the bathroom, and consider bed rails or a bedside commode if nocturia is frequent.

Cognitive Effects and Activities Requiring Mental Sharpness

Memory and Psychomotor Performance

Controlled studies measuring cognitive function the morning after suvorexant dosing show detectable but transient impairment. A randomized, double-blind crossover trial (N=62 older adults, mean age 69) used the Digit Symbol Substitution Test (DSST) and Word Learning Task to assess next-morning cognition after suvorexant 15 mg and 30 mg (doses higher than the current approved ceiling). Significant impairment on the DSST was observed at 9 hours post-dose with the 30 mg dose; the 15 mg dose showed a non-significant trend toward slowing. [8] At the approved 10 to 20 mg range, clinically meaningful residual impairment is less pronounced but cannot be excluded in individuals with slower hepatic clearance.

Activities That Warrant Caution

Older adults enrolled in structured learning programs, community college courses, certification training, or cognitively demanding volunteering should be counseled that morning classes scheduled within 6 to 7 hours of dosing carry a risk of impaired concentration and slower information processing. Scheduling suvorexant use on nights before low-demand mornings is a practical strategy. Patients managing financial accounts, operating medical devices (continuous positive airway pressure machines, insulin pumps), or supervising grandchildren should be aware of this window as well.

Complex Sleep Behaviors

The FDA issued a class-wide warning in 2019 for all prescription sleep aids, including suvorexant, regarding complex sleep behaviors such as sleepwalking, sleep driving, and sleep-related eating. [9] These behaviors, though rare (reported in post-marketing surveillance), present a specific safety risk for older adults because injury from a fall during a complex sleep behavior episode could be catastrophic. The label states these behaviors can occur at any dose and that patients who experience them should discontinue the medication and contact their provider. [1]

Physical Activity and Exercise Timing Around Suvorexant Use

Morning Exercise

A 7-hour minimum time in bed is the standard guidance before any activity requiring full psychomotor function. Morning exercise, particularly activities with significant balance or coordination demands (cycling, swimming, tai chi, yoga), should be delayed until residual sedation has cleared. A pragmatic approach: patients who plan a 6 a.m. Gym session should take suvorexant no later than 11 p.m. And should self-assess alertness before leaving the house.

Afternoon and Evening Exercise

Aerobic exercise performed in the afternoon (not within 1 to 2 hours of bedtime) does not appear to reduce suvorexant efficacy in available data and may independently improve sleep quality. A meta-analysis of exercise interventions for insomnia in older adults (k=29 trials, N=2,017) found that moderate-intensity aerobic exercise reduced Pittsburgh Sleep Quality Index scores by a mean of 3.1 points (95% CI 2.3 to 3.9), an effect size that complements pharmacotherapy. [10] Prescribers managing older patients on suvorexant should actively encourage afternoon exercise as an adjunctive strategy.

Alcohol and Physical Activity Risk

Suvorexant's prescribing label warns against concurrent alcohol use because ethanol potentiates CNS depression. [1] Older adults who consume alcohol at evening social events and then take suvorexant are at substantially increased fall and sedation risk the following morning, compounding the activity restrictions outlined above.

Driving: A Detailed Risk Profile for Older Patients

Motor vehicle crashes are the second leading cause of injury-related death in adults aged 65 to 74 in the United States. [6] The morning-after driving risk from suvorexant deserves its own discussion beyond a simple caution.

The Vermeeren On-Road Study

The on-road driving study by Vermeeren et al. Enrolled adults with insomnia (mean age 63.5 years) and tested driving performance approximately 9 hours after a 20 mg suvorexant dose. SDLP was elevated by 3.5 cm above placebo (P<0.001), a statistically and clinically significant difference. [5] Importantly, subjective drowsiness ratings did not fully track objective impairment, meaning some participants felt alert yet performed poorly on the driving task. This dissociation between perceived and actual readiness is a well-documented feature of residual hypnotic impairment and is especially concerning in older drivers who may already have reduced self-assessment accuracy.

Regulatory Guidance

The FDA's guidance document on drug-impaired driving notes that even a single nighttime dose of certain sleep medications can produce driving impairment the following morning that is legally and clinically meaningful. [9] Older patients should be explicitly told: if you feel drowsy the morning after taking Belsomra, do not drive, regardless of how many hours have passed since the dose.

Clinical Counseling Script

A practical prescriber-patient framework for driving safety with suvorexant in adults 65 and older:

1. Dose timing audit. Confirm the patient reliably takes the dose at least 7.5 hours before planned wake time.
2. Morning self-check. Before any driving, the patient performs a 60-second balance test: stand on one foot for 10 seconds per side. Failure or marked instability = do not drive.
3. Caregiver loop-in. If a spouse or household member is present, ask them to confirm the patient appears alert before driving.
4. Dose review at 4 weeks. If daytime sedation persists, return to 10 mg or trial a non-pharmacological sleep intervention.

Interactions With Other Medications Common in Geriatric Patients

CYP3A Inhibitors and the Activity Window

Suvorexant is metabolized primarily by CYP3A4. Concomitant use of moderate CYP3A4 inhibitors (fluconazole, diltiazem, verapamil) increases suvorexant plasma exposure and prolongs its half-life, extending the residual sedation window beyond the standard 7-hour estimate. [1] Older adults are more likely than younger adults to be on these agents, which are commonly prescribed for cardiovascular or fungal indications. The prescribing information recommends a starting dose of 5 mg when a moderate CYP3A4 inhibitor is co-administered, though 5 mg is not a commercially available tablet; prescribers should discuss this with the dispensing pharmacy. Strong CYP3A4 inhibitors (clarithromycin, ketoconazole) are a contraindication per the label. [1]

CNS Depressants and Polypharmacy

A 2022 cross-sectional analysis using Medicare Part D data found that 41% of community-dwelling adults aged 65 and older who received a prescription sleep medication were concurrently dispensed at least one other CNS-active agent (benzodiazepines, gabapentinoids, opioids, or antidepressants with sedating properties). [11] Additive sedation from polypharmacy substantially widens the impairment window and increases fall risk beyond what suvorexant alone would produce. A medication reconciliation review at each visit is the minimum standard of care.

Comparing Suvorexant to Other Sleep Agents in Geriatric Patients

The American Geriatrics Society Beers Criteria (2023 update) lists benzodiazepines and non-benzodiazepine hypnotics (zolpidem, eszopiclone, zaleplon) as potentially inappropriate medications in older adults due to their association with cognitive impairment, delirium, falls, and motor vehicle crashes. [12] Suvorexant is not included in the 2023 Beers list as a potentially inappropriate agent, though the criteria note that all sleep aids carry residual sedation risk.

A head-to-head randomized trial comparing suvorexant 10 to 20 mg versus zolpidem 5 mg in adults aged 65 and older (N=285) found comparable sleep onset and maintenance efficacy, with suvorexant producing numerically fewer next-morning psychomotor adverse events (3.2% vs. 6.4%), though the trial was not powered to detect a statistically significant difference between groups. [13]

Practical Scheduling Recommendations for Older Adults

Nighttime Routine

Take suvorexant within 30 minutes of planned sleep onset, with at least 7 hours remaining before the alarm. Do not take the drug after a high-fat meal, which delays the time to peak plasma concentration (Tmax shifts from approximately 2 hours to approximately 3 hours) and may compress the morning safety window. [1]

Morning Activity Ladder

Not all morning activities carry equal risk. A tiered approach based on residual sedation hazard:

| Risk Tier | Activity Examples | Minimum Post-Dose Wait | |---|---|---| | High | Driving, power tools, cycling on roads, swimming alone | 7+ hours, confirm no drowsiness | | Moderate | Cooking with stove, stair climbing, supervised exercise class | 7 hours | | Low | Reading, computer work, phone calls, light stretching | 6 hours if alert | | Very Low | Passive activities (TV, audiobooks) | No restriction beyond personal alertness |

When to Contact a Prescriber

Patients should contact their prescriber if: next-day drowsiness persists beyond 10 a.m. On most days, they experience a fall within 2 hours of waking, they notice memory gaps from the previous night, or they find themselves falling asleep during activities they did not intend to sleep through (a signal for possible complex sleep behavior episodes or excessive drug accumulation).

Special Populations Within the 65+ Group

Adults aged 75 and older represent a distinct subpopulation with higher rates of polypharmacy, reduced hepatic mass, and greater baseline fall risk than adults aged 65 to 74. The suvorexant prescribing information does not provide a separate dose recommendation for patients over 75, but clinicians should apply extra caution. Starting at 10 mg and waiting at least 4 weeks before any dose escalation is the conservative clinical standard. [1]

Patients with mild-to-moderate hepatic impairment do not require dose adjustment per the label, but severe hepatic impairment is an exclusion from the prescribing information's recommendation, and suvorexant should be avoided in that setting. [1]

Patients with a history of narcolepsy, cataplexy, or sleep paralysis should not receive suvorexant, as blockade of orexin signaling could worsen these conditions. This exclusion is particularly relevant in older adults being evaluated for excessive daytime sleepiness. [14]

Summary Guidance for Prescribers Managing Older Patients on Suvorexant

A clinical checklist before prescribing suvorexant in a patient aged 65 or older:

• Confirm no strong CYP3A4 inhibitors in current medication list.
• Screen for concurrent CNS depressants; reconcile or taper before initiating.
• Assess fall history and gait; consider referral to physical therapy for balance training before or concurrent with sleep pharmacotherapy.
• Instruct patient on the 7-hour rule and the morning self-check described above.
• Document counseling on driving impairment in the clinical note.
• Schedule a 4-week follow-up to assess daytime sedation and activity function.
• Reassess annually whether pharmacotherapy remains the optimal insomnia management approach, given that Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment by the American College of Physicians for chronic insomnia in all adults. [15]

The starting dose for adults 65 and older is 10 mg nightly; do not exceed 20 mg in this age group per FDA labeling. [1]